New Injectable Gel Delivers Exenatide Slowly for Long-Lasting Blood Sugar Control
A dual-phase delivery system combining nanoparticles with a temperature-sensitive hydrogel provided sustained exenatide release and prolonged blood sugar control in diabetic rats.
Quick Facts
What This Study Found
The biphasic delivery system (Ex-NPs-gel) provided both rapid initial and sustained long-term exenatide release, achieving prolonged glycemic control compared to standard exenatide injections in diabetic rats.
Key Numbers
- Sustained release over 31 days in vitro
- Initial burst release below 9% in first 24 hours
- Single injection stabilized blood glucose for 15+ days in diabetic rats
- Restored hepatic and pancreatic functions
How They Did This
Animal study developing and testing PLGA nanoparticles loaded with exenatide, embedded in PLGA-PEG-PLGA thermosensitive hydrogel. Characterized particle properties and release kinetics, then tested in vivo glycemic control in diabetic rat models.
Why This Research Matters
Poor patient compliance due to frequent injections is a major barrier for GLP-1 agonist therapy. A single injection that provides weeks of drug release could dramatically improve treatment adherence and outcomes for millions of diabetes patients.
The Bigger Picture
This delivery approach could be applied to many peptide drugs that currently require frequent injections. If successful in humans, it could transform how GLP-1 agonists and other peptide therapeutics are administered, making treatment more convenient and effective.
What This Study Doesn't Tell Us
Animal study only — rat pharmacokinetics differ from human; long-term biocompatibility of implanted hydrogel needs assessment; manufacturing scalability and cost not addressed; comparison with existing long-acting formulations (weekly semaglutide) not performed.
Questions This Raises
- ?How long does a single injection provide therapeutic exenatide levels compared to weekly injectable formulations?
- ?Is the hydrogel fully biodegradable, and does it cause any local tissue reaction?
- ?Could this delivery platform be adapted for other peptide drugs like semaglutide or liraglutide?
Trust & Context
- Key Stat:
- Dual-phase release Nanoparticle-hydrogel system provides rapid initial then sustained exenatide delivery from a single injection
- Evidence Grade:
- Preclinical proof-of-concept in animal models. Demonstrates technical feasibility but requires extensive further development for clinical use.
- Study Age:
- Published in 2025, reflecting ongoing innovation in peptide drug delivery systems.
- Original Title:
- Dual-phase exenatide delivery system: PLGA nanoparticles embedded in thermosensitive PLGA-PEG-PLGA hydrogel for sustained glycemic control.
- Published In:
- Expert opinion on drug delivery, 22(12), 2001-2015 (2025)
- Authors:
- Pan, Shu, Dong, Nan, Yuan, Haoyang(2), Zhang, Yu, He, Haibing, Yin, Tian, Wang, Yanjiao, Gou, Jingxin, Tang, Xing
- Database ID:
- RPEP-12930
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How does a thermosensitive hydrogel work?
The gel is liquid at room temperature, making it easy to inject. Once inside the body at 37°C, it solidifies into a gel depot that slowly releases the drug over time. Think of it as a tiny drug reservoir that forms automatically under the skin.
Why can't people just take exenatide as a pill?
Like most peptide drugs, exenatide is a small protein that would be destroyed by stomach acid and digestive enzymes if swallowed. That's why it needs to be injected, and why researchers are developing sustained-release systems to reduce how often injections are needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12930APA
Pan, Shu; Dong, Nan; Yuan, Haoyang; Zhang, Yu; He, Haibing; Yin, Tian; Wang, Yanjiao; Gou, Jingxin; Tang, Xing. (2025). Dual-phase exenatide delivery system: PLGA nanoparticles embedded in thermosensitive PLGA-PEG-PLGA hydrogel for sustained glycemic control.. Expert opinion on drug delivery, 22(12), 2001-2015. https://doi.org/10.1080/17425247.2025.2564870
MLA
Pan, Shu, et al. "Dual-phase exenatide delivery system: PLGA nanoparticles embedded in thermosensitive PLGA-PEG-PLGA hydrogel for sustained glycemic control.." Expert opinion on drug delivery, 2025. https://doi.org/10.1080/17425247.2025.2564870
RethinkPeptides
RethinkPeptides Research Database. "Dual-phase exenatide delivery system: PLGA nanoparticles emb..." RPEP-12930. Retrieved from https://rethinkpeptides.com/research/pan-2025-dualphase-exenatide-delivery-system
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.